DAWN (Drug-Assisted Weight Normalization): Normalizing the Pursuit for Health
DOI:
https://doi.org/10.59793/gpygaj43Keywords:
Antiobesity medications,, GLP-1 receptor agonists,, incretin therapy,, medical management of obesityAbstract
Obesity is accepted as a disease by professional organizations across the world. The rise in its prevalence has been matched
by enhanced understanding of its causation, clinical trajectory as well as complications. Endocrinologists are now able to
treat obesity with a variety of interventions, including behavioral, dietary, oral, injectable, invasive, and surgical therapies.
In this manuscript, we describe highly effective antiobesity medications available for weight loss.
Downloads
Published
Issue
Section
License
All open access articles published in IJCP are distributed under the terms of the CC BY-NC 4.0 license (Creative Commons Attribution-Non-Commercial 4.0 International Public License). This license permits unrestricted use, distribution, and reproduction of the articles in any medium for non-commercial purposes, provided that: The original authorship is properly and fully attributed. The IJCP is cited as the original place of publication with correct citation details. If an original work is reproduced or disseminated in part or as a derivative work, this must be clearly indicated. No articles are reproduced for commercial use without prior consent from the IJCP. All licensing requests and permissions for commercial use will be managed by the Publisher.
How to Cite
